ZBTB16 and acute promyelocytic leukemia: The World Health Organization (WHO) classification system has reclassified these cases as “APL with variant RARA translocation” (16).These cases differ from classical APL in their biological characteristics and response to ATRA (all-trans retinoic acid) dosing, examples include: The ZBTB16-RARA fusion is the result of a reciprocal translocation that involves the ZBTB16 gene located on chromosome11 and the RARA gene situated on chromosome 17 [t(11;17)(q23;q21)].This variant is the most frequently reported and accounts for approximately 1% of all cases of APL (17, 18).